03/01/1981 - "By contrast, when the analysis was limited to legs with claudication pain, a significant improvement occurred only in the suloctidil-treated group. "
03/01/1981 - "These findings suggest that suloctidil may improve the claudication symptoms of patients with chronic arterial obstructive disease and in particular the perfusion of legs experiencing claudication pain. "
01/01/1982 - "In a recent double-blind trial lasting over 6 months, 40 patients suffering from intermittent claudication were randomly allocated to receive 300 mg of suloctidil per day or exactly matching placebo capsules. "
01/01/1982 - "A double-blind trial of suloctidil v. placebo in intermittent claudication."
03/01/1981 - "Controlled trial of suloctidil in intermittent claudication."
01/01/1984 - "Intermittent claudication: Suloctidil v.s. "
03/01/1981 - "Forty-five patients with intermittent claudication were first treated with placebo tablets for 3 months and then randomly allocated to double-blind therapy with either suloctidil or placebo for 6 months. "
05/01/1985 - "A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke."
05/01/1985 - "Four hundred and thirty-eight patients who had suffered a thromboembolic stroke not less than two weeks or more than four months previously, were entered into a placebo-controlled randomized clinical trial to determine whether suloctidil (200 mg t.i.d.) would influence the subsequent recurrence of stroke, the occurrence of myocardial infarction, or cardiovascular death. "
06/01/1994 - "The established role of platelet aggregation in TIA or minor and major ischaemic stroke has provided the rationale for many randomized trials of antiplatelet agents (aspirin, sulfinpyrazone, dipyridamole alone or in combination with aspirin, suloctidil, ticlopidine). "
10/01/1985 - "[Hepatitis caused by suloctidil]."
03/01/1985 - "[Fulminating hepatitis due to suloctidil]."
11/01/1984 - "[Hepatitis from suloctidil (Fluvisco)]."
10/06/1984 - "[Suloctidil hepatitis: bringing into focus]."
06/01/1984 - "[Another cirrhogenic hepatitis from suloctidil (Fluvisco)]."
|5.||Venous Thrombosis (Deep-Vein Thrombosis)
07/15/1985 - "Major deep vein thrombosis occurred in two patients on suloctidil and three patients in the placebo group; there were no fatal pulmonary emboli during the 14-day study period, during which time four patients in each group died of non-thromboembolic complications. "
07/15/1985 - "Seventeen of 68 patients (25%) (95% confidence interval, 15-35%) treated with suloctidil and 12 of 68 patients (21%) (95% confidence interval, 11-32%) treated with placebo developed deep venous thrombosis. "
07/15/1985 - "An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients."
07/15/1985 - "Suloctidil (200 mg t.i.d.) was compared with placebo in a randomized, double-blind trial to assess its value in preventing deep venous thrombosis (DVT) in high-risk neurosurgical patients, comprising 136 patients with brain or spinal tumour, head or spinal injury, or subarachnoid or intracranial hemorrhage. "
05/01/1986 - "Prolongation of a shortened platelet survival in man was considered to be one of the key markers of an anti-aggregatory agent; this characteristic was found to be present after administration of sulphinpyrazone, clofibrate, ticlopidine, suloctidil, dipyridamole (in patients with artificial heart valves) and dipyridamole (in patients with venous thrombosis). "
|4.||Platelet Aggregation Inhibitors (Antiplatelet Drugs)
|5.||Aspirin (Acetylsalicylic Acid)
|6.||Aspartate Aminotransferases (Aspartate Transaminase)
|7.||Alanine Transaminase (SGPT)
|1.||Artificial Heart (Artificial Hearts)
|2.||Drug Therapy (Chemotherapy)